

Adamas Pharmaceuticals Inc
Form 4
June 21, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
GREAT POINT PARTNERS LLC

2. Issuer Name and Ticker or Trading Symbol
Adamas Pharmaceuticals Inc
[ADMS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2017

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

165 MASON STREET, 3RD FLOOR,

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

GREENWICH, CT 06830

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				(A) or (D)	Price				
				Code	V	Amount			
Common Stock	06/19/2017		S	D	350,000 (1)	\$ 17.0505	2,251,351 (2)	I	Investment Mgr. (3)
Common Stock	06/20/2017		S	D	20,000 (4)	\$ 17.3467	2,231,351 (5)	I	Investment Mgr. (3)
Common Stock	06/21/2017		S	D	10,000 (6)	\$ 17.4365	2,216,351 (7)	I	Investment Mgr. (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

SEC 1474 (9-02)

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(2) Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(3) Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

(4) Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(5) Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(6) Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(7) Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.